BibTex RIS Kaynak Göster

-

Yıl 2014, , 231 - 240, 29.03.2014
https://doi.org/10.7197/cmj.v36i2.5000012436

Öz

Aim. Atherosclerosis is regarded as a chronic inflammatory disease developing in response to injury in the vessel wall. Inflammation plays a key role in the development of atherosclerosis. Interleukin- 1α (IL-1α) has a critical role on regulation of proinflammation. The aim the study was to assess the relationship between the IL-1α -889 C/T polymorphism and the atherosclerosis. Method. The study population was composed of 117 patients (Group I) and 117 healthy adults (Group II). Genomic DNA of case and control was extracted from blood leukocytes. IL-1α genotype were further confirmed by direct sequencing of randomly selected samples. Results. 78 male and 39 female individuals in the group I, 49 men and 68 women in Group II. The average age of individuals in the Group I 61.06, the average age of individuals in the Group II 59.47 years old. The Group I 43 and the Group II were detected in 28 individuals with high cholesterol(total cholesterol>200 mg/dL). 62 individuals in the Group I and 51 individuals in the Group II was smoking. The Group I 81 individuals with high blood pressure(systolic blood pressure>140 mmHg and / or diastolic blood pressure>90 mmHg), 42 individuals with diabetes, the Group II 32 individuals with high blood pressure, diabetes was found 41 individuals. In the atherosclerotic coronary artery patients of %54.70 individuals carrying the CC genotype, %35.04 individuals carrying the CT genotype and %10.25 individuals carrying the TT genotype constitutes. In the healty control group, %59.82 individuals carrying the CC genotype, %30.76 individuals carrying CT genotype and %9.40 individuals carrying TT genotype. IL-1α polymorphism of C allele frequency is %75.21 in the Group II and %72.22 in the Group I. T allele freguency distribution of %24.78 in the Group II and %27.77 in the Group I. Conclusion. Those with coronary artery disease group between the Group II age, sex distribution, hypertension and hypercholesterolemia were found statistically significant relationship. There was no statistically significant difference between groups according to the IL-1α-889 C/T gene polymorphism.

Kaynakça

  • Zengin H. Ateroskleroz patogenezi J. Exp. Clin. Med 2012; 29:101-6.
  • Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: A clinicobiochemical perspective. Angiology 2007; 58: 513Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-6.
  • Borish L, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111: 460-75.
  • Lendon LC, Davies MJ, Born GVR, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 1991; 87: 87-90.
  • Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in Acute Coronary Syndromes. Circulation 1994; 90: 775-8.
  • Tsimikas S, Witztum JL. Measuring circulating oxidized Low-Density lipoprotein to evaluate coronary risk. Circulation 2001; 103: 1930-2.
  • Arend WP. The balance between IL-1 and IL-1 Ra in disease. Cytokine Growth Factor Rev 2002; 13: 323-40.
  • Clay FE, Cork MJ, Tarlow JK, Blakemore AI, Harrington CI. Interleukin-1 receptor antagonist gene polymorphism associated with lichen sclerosus. Human Genetics 1996; 94: 404-10.
  • Zheng Zhang, Li-Jun Liu, Chen Zhang, Yong-Peng Yu. Association between Interleukin-1 Gene Single Nucleotide Polymorphisms and Ischemic Stroke Classified by TOAST Criteria in the Han Population of Northern China. Biomed Res Int 2013: 961039.
  • Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A laboratory manual. 2nd ed. N.Y. Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press 1989; 1659.
  • Onat A. Erişkinlerimizde kalp hastalakları prevalansi, yeni koroner olaylar ve kalpten ölüm sıklığı. TEKHARF (Türk erişkinlerinde kalp hastalığı ve risk faktörleri) 2009.
  • Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-9
  • Özkan Y, Koca SS, Gürsu F, Sonkaya E, Poyrazoğlu OK, Dönder E. Hiperlipidemik Hastalarda Atorvastatin Tedavisinin Serum Paraoksonaz-1 Düzeyine Etkisi. Fırat Tıp Dergisi 2004; 9: 123-6.
  • Tokgözoğulu L, Özer N. Ateroskleroz patogenezi. Özcan N. Koroner kalp hastalıkları. 1. Baskı. Ankara 1997; 129-63.
  • Gordon DJ, Probstfeld JL, Garrison RJ. High-density lipoprotein cholesterol and cardiovascular disase: Four prospective American study. Circulation 1989; 37: 47-5
  • Algün E, Şekeroğlu R, Erkoç R, Özbek H, Alcı S, İlhan M ve ark. Sigara İçen Sağlıklı Gönüllülerde Çeşitli Aterosklerotik Risk Faktörlerinin Araştırılması ve Düşük Doz ACE İnhibitörü Kullanımının Bu Parametreler Üzerine Etkisi. Van Tıp Dergisi 1999; 6: 10-4.
  • Franklin SS, Gustin W, Wong ND. Hemodynamic patterns of age related changes in blood pressure. The Framingham Heart Study.Circulation 1997; 96: 308-15.
  • DECODE Study Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria and European Diabetes Epidemiology Group. Lancet 1999; 354: 617-21.
  • Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006; 8: 2.
  • Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1-10.
  • Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable anjina and their reduction by aspirin. Circulation 1999; 100: 793-8. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U. ve ark. Cytokine expression in advanced human atherosclerotic plaques: Dominance of proinflammatory (Th1) and macrophage stimulating cytokines. Atherosclerosis 1999; 145: 33-43.
  • Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK ve ark Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-8.
  • Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: The central role of interleukin-6. Eur Heart J 2000; 21: 1574-83.
  • Francis SE, Camp NJ, Burton AJ, Dewberry RM, Gunn J, Stephens-Lloyd A. ve ark.Interleukin -1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999; 99: 861-6.
  • Kastrati A, Koch W, Berger PB, Mehilli J, Stephenson K, Neumann FJ et al. Protective role against restenosis from an interleukin -1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 2000; 362168-73.
  • Shimada K, Watanabe Y, Mokuno H, Iwama Y, Daida H, Yamaguchi H. Common polymorphism in the promoter of the CD14 monocyte receptor gene is associated with acute myocardial infarction in Japanese men. Am J Cardiol 2000; 86: 682-4.
  • Francis SE, Camp NJ, Burton AJ, Dewberry RM, Gunn J, Stephens- Lloyd A et al. IL-1Ra gene polimorphism and restenosis after coronary angioplasty. Heart 2001; 86: 336-40.
  • Vohnout B, Di Castelnuovo A, Trotta R, D’Orazi A, Panniteri G, Montali A et al. IL-1 gene cluster polimorphisms and risk of coronary artery disease. Haematologica 2003; 88: 54-60.
  • Banerje I, Pandey U, Hasan O, Parihar R. Association between inflammatory gene polymorphismsand coronary artery disease in an Indian population. J Thromb Thrombolysis 2009; 27: 88-94.

Ateroskleroz ile il-1α (interleukin-1α -889 c/t) gen polimorfizmi arasındaki ilişkinin araştırılması

Yıl 2014, , 231 - 240, 29.03.2014
https://doi.org/10.7197/cmj.v36i2.5000012436

Öz

Amaç. Genetik ve çevresel faktörler arasındaki ilişki sonucu ortaya çıkan kardiyovasküler
hastalıkların gelişiminde inflamasyon anahtar rol oynamaktadır. İnterlökin-1α (IL-1α) nın
proinflamasyon regülasyonunda önemli rolü vardır. Bu çalışmada IL-1α-889 C/T polimorfizmi ile
ateroskleroz arasındaki ilişkinin araştırılması amaçlanmıştır. Yöntem. Bu çalışma popülasyonu
117 hasta (Grup I) ve 117 sağlıklı (Grup II) bireyden oluşmuştur. Grup I ve Grup II deki bireylerin
genomik DNA’sı izole edildi. IL-1α genotipleri rastgele seçilen örneklerden direkt dizi analizi
yapılarak doğrulandı. Bulgular. Grup I 78 erkek ve 39 kadın bireyden, Grup II ise 49 erkek ve 68
kadın bireyden oluşmaktadır. Grup I bireylerin yaş ortalaması 61,06; Grup II bireylerin yaş
ortalaması ise 59,47’dir. Grup I’de 43 bireyde, Grup II’de ise 28 bireyde yüksek kolesterol (total
kolesterol > 200 mg/dL) bulundu. Grup I’de 62 bireyde, Grup II’de 51 bireyde sigara içiciliği
bulundu. Grup I’de 81 bireyde yüksek tansiyon ( sistolik kan basıncı > 140 mmHg ve/veya
diyastolik kan basıncı > 90 mmHg), 42 bireyde diyabet, Grup II’de 32 bireyde yüksek tansiyon, 41
bireyde diyabet bulundu. Aterosklerotik Grup I’de CC genotip taşıyan bireyler grubun %54,70’ini,
CT genotip taşıyan bireyler %35,04’nü ve TT genotip taşıyan bireyler ise %10,25’ini
oluşturmaktadır. Grup II’de ise bu oranlar CC genotip taşıyanlarda %59,82; CT genotip
taşıyanlarda %30,76 ve TT genotip taşıyanlarda %9,40 olarak saptanmıştır. IL-1α polimorfizmi
için C allel frekansı Grup II’de %75,21 ve Grup I’de %72,22’dir. T allel frekansı dağılımı Grup
II’de %24,78 ve Grup I’de ise %27,77’dir. Sonuç. Koroner Arter hastalığı olan Grup I ile, kontrol
grubu olan Grup II arasında yaş, cinsiyet dağılımı, hipertansiyon ve hiperkolesterolemi açısından
istatistiksel olarak anlamlı bir ilişki saptanmıştır. Grup I ile Grup II arasında IL-1α-889 C/T gen
polimorfizmi açısından istatistiksel olarak anlamlı bir ilişki saptanmamıştır.

Kaynakça

  • Zengin H. Ateroskleroz patogenezi J. Exp. Clin. Med 2012; 29:101-6.
  • Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: A clinicobiochemical perspective. Angiology 2007; 58: 513Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-6.
  • Borish L, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111: 460-75.
  • Lendon LC, Davies MJ, Born GVR, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 1991; 87: 87-90.
  • Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in Acute Coronary Syndromes. Circulation 1994; 90: 775-8.
  • Tsimikas S, Witztum JL. Measuring circulating oxidized Low-Density lipoprotein to evaluate coronary risk. Circulation 2001; 103: 1930-2.
  • Arend WP. The balance between IL-1 and IL-1 Ra in disease. Cytokine Growth Factor Rev 2002; 13: 323-40.
  • Clay FE, Cork MJ, Tarlow JK, Blakemore AI, Harrington CI. Interleukin-1 receptor antagonist gene polymorphism associated with lichen sclerosus. Human Genetics 1996; 94: 404-10.
  • Zheng Zhang, Li-Jun Liu, Chen Zhang, Yong-Peng Yu. Association between Interleukin-1 Gene Single Nucleotide Polymorphisms and Ischemic Stroke Classified by TOAST Criteria in the Han Population of Northern China. Biomed Res Int 2013: 961039.
  • Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A laboratory manual. 2nd ed. N.Y. Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press 1989; 1659.
  • Onat A. Erişkinlerimizde kalp hastalakları prevalansi, yeni koroner olaylar ve kalpten ölüm sıklığı. TEKHARF (Türk erişkinlerinde kalp hastalığı ve risk faktörleri) 2009.
  • Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-9
  • Özkan Y, Koca SS, Gürsu F, Sonkaya E, Poyrazoğlu OK, Dönder E. Hiperlipidemik Hastalarda Atorvastatin Tedavisinin Serum Paraoksonaz-1 Düzeyine Etkisi. Fırat Tıp Dergisi 2004; 9: 123-6.
  • Tokgözoğulu L, Özer N. Ateroskleroz patogenezi. Özcan N. Koroner kalp hastalıkları. 1. Baskı. Ankara 1997; 129-63.
  • Gordon DJ, Probstfeld JL, Garrison RJ. High-density lipoprotein cholesterol and cardiovascular disase: Four prospective American study. Circulation 1989; 37: 47-5
  • Algün E, Şekeroğlu R, Erkoç R, Özbek H, Alcı S, İlhan M ve ark. Sigara İçen Sağlıklı Gönüllülerde Çeşitli Aterosklerotik Risk Faktörlerinin Araştırılması ve Düşük Doz ACE İnhibitörü Kullanımının Bu Parametreler Üzerine Etkisi. Van Tıp Dergisi 1999; 6: 10-4.
  • Franklin SS, Gustin W, Wong ND. Hemodynamic patterns of age related changes in blood pressure. The Framingham Heart Study.Circulation 1997; 96: 308-15.
  • DECODE Study Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria and European Diabetes Epidemiology Group. Lancet 1999; 354: 617-21.
  • Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006; 8: 2.
  • Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1-10.
  • Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable anjina and their reduction by aspirin. Circulation 1999; 100: 793-8. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U. ve ark. Cytokine expression in advanced human atherosclerotic plaques: Dominance of proinflammatory (Th1) and macrophage stimulating cytokines. Atherosclerosis 1999; 145: 33-43.
  • Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK ve ark Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-8.
  • Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: The central role of interleukin-6. Eur Heart J 2000; 21: 1574-83.
  • Francis SE, Camp NJ, Burton AJ, Dewberry RM, Gunn J, Stephens-Lloyd A. ve ark.Interleukin -1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999; 99: 861-6.
  • Kastrati A, Koch W, Berger PB, Mehilli J, Stephenson K, Neumann FJ et al. Protective role against restenosis from an interleukin -1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 2000; 362168-73.
  • Shimada K, Watanabe Y, Mokuno H, Iwama Y, Daida H, Yamaguchi H. Common polymorphism in the promoter of the CD14 monocyte receptor gene is associated with acute myocardial infarction in Japanese men. Am J Cardiol 2000; 86: 682-4.
  • Francis SE, Camp NJ, Burton AJ, Dewberry RM, Gunn J, Stephens- Lloyd A et al. IL-1Ra gene polimorphism and restenosis after coronary angioplasty. Heart 2001; 86: 336-40.
  • Vohnout B, Di Castelnuovo A, Trotta R, D’Orazi A, Panniteri G, Montali A et al. IL-1 gene cluster polimorphisms and risk of coronary artery disease. Haematologica 2003; 88: 54-60.
  • Banerje I, Pandey U, Hasan O, Parihar R. Association between inflammatory gene polymorphismsand coronary artery disease in an Indian population. J Thromb Thrombolysis 2009; 27: 88-94.
Toplam 29 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Cerrahi Tıp Bilimleri Araştırma Yazıları
Yazarlar

Hasan Basçil

Erhan Atahan

Müslim Gül

Serdal Arslan

Nil Ozbilum

Öcal Berkan

Yayımlanma Tarihi 29 Mart 2014
Yayımlandığı Sayı Yıl 2014

Kaynak Göster

AMA Basçil H, Atahan E, Gül M, Arslan S, Ozbilum N, Berkan Ö. Ateroskleroz ile il-1α (interleukin-1α -889 c/t) gen polimorfizmi arasındaki ilişkinin araştırılması. CMJ. Haziran 2014;36(2):231-240. doi:10.7197/cmj.v36i2.5000012436